This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism (VERITAS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2014 by Veniti.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Veniti
ClinicalTrials.gov Identifier:
NCT01787773
First received: February 6, 2013
Last updated: June 26, 2014
Last verified: June 2014
February 6, 2013
June 26, 2014
March 2013
April 2015   (Final data collection date for primary outcome measure)
Clinical Success [ Time Frame: 6 months ]

The endpoint is clinical success (versus failure) at 6 months after implant or 1 month post retrieval, whichever occurs first, based on the definition provided by the SIR guidelines, as the absence of:

  • Procedure failure (assessed at the end of the implant procedure)
  • Subsequent pulmonary embolus
  • IVC occlusion
  • Filter embolization
Same as current
Complete list of historical versions of study NCT01787773 on ClinicalTrials.gov Archive Site
  • Secondary Endpoint [ Time Frame: 24 months ]

    Estimating the rate of:

    • Retrieval success
    • Device and procedure related adverse events
  • filter performance rate [ Time Frame: 24 months ]

    Assessing filter performance rate:

    • Filter migration
    • Filter fracture
    • Filter Tilt
Same as current
Not Provided
Not Provided
 
VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism
VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism
This is a prospective, multicenter single arm, nonrandomized study that will include 150 patients at a maximum of 20 investigational sites. It is estimated that it may take 13 months to complete enrollment. Follow-up will continue through 24 months post-implant or one month post-retrieval, whichever occurs first. It is required that filters be retrieved from at least 50 patients and the filter is permanent in at least 50 patients.

Verify the effectiveness and safety of the Veniti IVC Filter in accordance with the clinical guidelines published by the Society for Interventional Radiology (SIR) .

The endpoint is clinical success (versus failure) at 6 months after implant or 1 month post retrieval, whichever occurs first, based on the definition provided by the SIR guidelines, as the absence of:

  1. Procedure failure (assessed at the end of the implant procedure)
  2. Subsequent pulmonary embolus
  3. IVC occlusion
  4. Filter embolization

Secondary assessments include:

Estimating the rate of:

  1. Retrieval success
  2. Device and procedure related adverse events
  3. Assessing filter performance rate:

c1.Filter migration c2.Filter fracture c3.Filter Tilt

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Deep Vein Thrombosis
  • Pulmonary Embolus
Device: Veniti Inferior Vena Cava Filter
Experimental: Veniti Inferior Vena Cava Filter
Intervention: Device: Veniti Inferior Vena Cava Filter
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
150
April 2017
April 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • ≥ 18 years
  • Investigator judges caval filtration clinically indicated for prevention of pulmonary embolism in patient with venous thromboembolic disease or at high risk for venous thromboembolic disease. Patient must meet at least one of the following:
  • Anticoagulant therapy is contraindicated, has failed, cannot be achieved or maintained, must be interrupted, resulted in complication, or places the patient at high risk of complication and the patient has:
  • Pulmonary embolus
  • Iliocaval deep vein thrombosis (DVT)
  • Severe trauma with high risk of venous thromboembolism including closed head injury, spinal cord injury, or multiple long bone or pelvic fractures
  • Surgery planned with high risk of venous thromboembolism including procedures such as bariatric, orthopedic, or pelvic surgery
  • Past history of thromboembolic disease undergoing surgery

Therapeutic anticoagulation can be achieved, but the patient has:

  • Venous thromboembolism such as pulmonary embolism or DVT with limited cardiopulmonary reserve
  • Massive pulmonary embolism already treated with thrombectomy or any thrombolytic therapy
  • Chronic pulmonary embolism already treated with thrombectomy
  • Large, free floating proximal, e.g., iliofemoral or iliocaval, DVT
  • Iliocaval DVT with planned catheter thrombectomy or thrombolysis treatment OR
  • Medical condition with high risk of venous thromboembolism

Exclusion Criteria:

  • Condition that inhibits radiographic visualization of the IVC
  • Known inadequate venous anatomy to allow insertion or retrieval of the filter from the IVC including occlusion of the SVC or jugular veins
  • Known IVC transverse diameter at target implant site > 28 mm
  • Known obstructing abdominal mass or anatomy that is not suitable for infra-renal placement of IVC filter
  • Known duplication of IVC or left-sided IVC
  • Severe kyphosis or scoliosis
  • Known IVC thrombosis extending to renal veins, or renal or gonadal vein thrombosis
  • Risk for septic pulmonary embolism
  • Confirmed bacteremia
  • Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min, or dialysis dependent.
  • Contrast agent allergy that cannot be adequately pre-medicated
  • Known hypersensitivity to Nitinol (nickel-titanium), platinum, Polyether ether ketone (PEEK), UV Cure Adhesive or Cyanoacrylate Adhesive
  • Uncontrolled or active coagulopathy or known uncorrectable bleeding diathesis
  • Life expectance < 6 months
  • Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study. (If a female of child bearing potential wishes to participate, she must have negative pregnancy test within 48 hours of the implantation and any retrieval procedures.)
  • Has filter in place or underwent filter retrieval in previous 60 days
  • Simultaneously participating in another therapeutic drug or device clinical trial or has participated in such trial in the 30 days prior to enrollment
  • Investigator considers patient to be a poor candidate for the study or that including the patient may compromise the study, e.g., suspect patient may not comply with follow up procedures, concomitant conditions
  • Patient does not wish to consent to study or comply with study procedures, including possible 2 year follow up
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   New Zealand
 
 
NCT01787773
FIL-HUM-002P
ACTRN12612001255875 ( Other Identifier: Australian New Zealand Clinical Trials Registry )
No
Not Provided
Not Provided
Not Provided
Veniti
Veniti
Not Provided
Not Provided
Veniti
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP